Effectiveness and safety of polytrope therapy with Thiotriazoline in patients with NAFLD and CHD. Results of the TRIGON-2 observational program
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Introduction. Risk factors and pathogenesis of non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD) overlap and complement each other. This makes it difficult to develop optimal patient management protocols and encourages the search for new approaches to the treatment of comorbid patients through the use of drugs that affect common pathogenetic mechanisms. One of such potential drugs with a polytropic effect on the cardiovascular system and hepatogenic-biliary system is morpholinium-methyl-triazolyl-thioacetate (Thiotriazoline). Aim. To prove the effectiveness of polytropic therapy with Thiotrizoline when using a step-by-step treatment regimen in comorbid patients with NAFLD and stable angina pectoris of functional class II. Materials and methods. A “Comparative study of the efficacy and safety of treatment with Thiotriazoline in patients with NAFLD and SAP II FC, TRIGON-2” was conducted. The study included 54 patients who were randomized into 2 groups. Group 1 “Basic”: in addition to basic therapy, patients received Thiotriazoline 2.5% solution intravenously, 4 ml in dilution per 150-200 ml of saline solution for 5 days. Then, from the 6th to the 60th day of the study, patients received Thiotriazoline in oral tablets of 200 mg 3 times a day, without chewing, washed down with water. Overall, the course of treatment with Thiotriazoline was 60 days. Group 2 “Comparisons”: patients received only basic therapy. The dynamics of laboratory and instrumental parameters reflecting the state of the cardiovascular system and liver were evaluated. Results. Titriazoline has been shown to have a polytropic effect, including hepato- and cardioprotective, which is manifested in an improvement in the subjective signs of the disease, an improvement in liver function in the form of a decrease in cytolysis and cholestasis indicators starting from the 5th day of therapy, an improvement in the parameters of lipid metabolism, an improvement in the calculated liver fibrosis index, an improvement in attitudes towards the disease according to the Seattle questionnaire, improving the overall effectiveness of treatment in patients with NAFLD and stable angina pectoris of functional class II. Conclusions. The use of a stepwise treatment regimen with Thiotrizoline in comorbid patients with NAFLD and stable angina pectoris of functional class II is safe and effective, exerting not only hepatoprotective and cardioprotective effects, but also positively affecting the components of cardio-reno-hepato-metabolic syndrome.
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7225567533